This is a working overview of Certificate of analysis, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-06. Anything still debated is marked as such rather than presented as settled.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
| Property | Value | Notes |
|---|---|---|
| Common route | Intranasal | Also injected in some animal work |
| Solubility class | Freely soluble in water | Solid form is hygroscopic |
| Typical storage | About -20 degrees Celsius | Keep desiccated and dark |
| Purity method | Reverse-phase HPLC | Reported as area percent |
| Confirmatory method | Mass spectrometry | Verifies expected molecular mass |
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
== Sticky-end ligation == Restriction enzymes can generate a wide variety of ends in the DNA they digest, but in cloning experiments most commonly used restriction enzymes generate a 4-base single-stranded overhang called the sticky or cohesive end (exceptions include NdeI which generates a 2-base overhang, and those that generate blunt ends). These sticky ends can anneal to other compatible ends and become ligated in a sticky-end (or cohesive end) ligation. EcoRI for example generates an AATT end, and since A and T have lower melting temperature than C and G, its melting temperature Tm is low at around 6°C. For most restriction enzymes, the overhangs generated have a Tm that is around 15°C. For practical purposes, sticky end ligations are performed at 12-16°C, or at room temperature, or alternatively at 4°C for a longer period. For the insertion of a DNA fragment into a plasmid vector, it is preferable to use two different restriction enzymes to digest the DNA so that different ends are generated. The two different ends can prevent the religation of the vector without any insert, and it also allows the fragment to be inserted in a directional manner. When it is not possible to use two different sites, then the vector DNA may need to be dephosphorylated to avoid a high background of recircularized vector DNA with no insert. Without a phosphate group at the ends the vector cannot ligate to itself, but can be ligated to an insert with a phosphate group.
=== Elimination === Small amounts of metabolites (alpha-methyldopa and alpha-methyldopamine) were found after the administration of both single-doses and maintenance-doses of AMPT. Small amounts of methyltyramine and alpha-methylnoradrenaline were found in patients undergoing AMPT therapy. Urine analysis also recovered 45 to 88 percent of unchanged AMPT after drug ingestion. Of the total AMPT excreted, 50 to 60 percent appeared in urine within the first 8 hours and 80 to 90 percent appeared within 24 hours of oral administration.
On average, the temperature of the ocean surface in the tropical East Pacific is roughly 8–10 °C (14–18 °F) cooler than in the tropical West Pacific. The sea surface temperature (SST) of the West Pacific northeast of Australia averages around 28–30 °C (82–86 °F). SSTs in the East Pacific off the western coast of South America are closer to 20 °C (68 °F). Strong trade winds near the equator drive water away from the East Pacific and into the West Pacific. This water is slowly warmed by the Sun as it moves west along the equator, the wind stress acting on the ocean surface being balanced by a sea surface slope. One result of this is that sea levels near Indonesia are typically around 0.5 m (1.5 ft) higher than that near Peru. The warm surface waters collect in the western Pacific, with the result that the thermocline, the transitional zone between the warmer waters near the ocean surface and the cooler waters of the deep ocean, lies much deeper in the western Pacific, where it has an average depth of around 140 m (450 ft) compared to around 30 m (90 ft) in the East Pacific. At depth, the sloping surface thermocline helps reduce the east–west pressure difference due to the sea level slope, but below the thermocline, the pressure difference is still enough to drive the eastward flowing cold equatorial undercurrent. The cooler deep ocean water replaces the outgoing surface waters in the East Pacific, rising to the ocean surface in a process called upwelling.
== Modern dating methods == Radiometric dating has been carried out since 1905 when it was invented by Ernest Rutherford as a method by which one might determine the age of the Earth. In the century since then the techniques have been greatly improved and expanded. Dating can now be performed on samples as small as a nanogram using a mass spectrometer. The mass spectrometer was invented in the 1940s and began to be used in radiometric dating in the 1950s. It operates by generating a beam of ionized atoms from the sample under test. The ions then travel through a magnetic field, which diverts them into different sampling sensors, known as "Faraday cups," depending on their mass and level of ionization. On impact in the cups, the ions set up a very weak current that can be measured to determine the rate of impacts and the relative concentrations of different atoms in the beams.
In November 2025, YouTube terminated Peters' original channel for facilitating access to websites selling regulated goods, canceling two additional channels in April 2026 for "severe or repeated violations." Although he attempted to return to the platform with other channels, YouTube permanently terminated these accounts in April 2026, citing a violation of its terms of service regarding ban evasion. A November 2025 video of him injecting his then 17-year-old girlfriend with fat-dissolving peptides to reshape her jaw gained attention online. In a later stream, he injected influencer Jenny Popach with Aqualyx, a fat-dissolving acid. On December 27, 2025, Peters appeared in an interview with conservative political commentator Michael Knowles for The Daily Wire. In it, Peters described Vice President JD Vance as "subhuman" for his "recessed side profile" and for being "obese", asking, "How are you fat and expected to lead a country?" He agreed with Knowles's criticism of California governor Gavin Newsom as both a "degenerate" and a "liar" but said that, in a potential 2028 United States presidential election in which Newsom ran against Vance, he would vote for "Chad" Newsom for "mogging" (being more attractive than) Vance. The segment soon went viral online. Other clips of him from the interview, including one in which he described actress Sydney Sweeney as "malformed" with an "extremely recessed" upper maxilla and "eyes of doom with no infraorbital support", also went viral online.
Sources: en.wikipedia.org
Isabel Kershner; British-born Israeli journalist and author, who began reporting from Jerusalem for The New York Times; has worked as senior Middle East editor for The Jerusalem Report magazine; also written for The New Republic and has provided commentary on Middle East affairs on BBC Radio; latest book is "The Land of Hope and Fear: Israel's Battle for its Inner Soul"; married to South African born Israeli author Hirsh Goodman, an employee of the Institute for National Security Studies, which is involved in promoting a positive image of Israel, and which Kershner often relies on as a source. Ian Katz (born 9 February 1968) of South African Jewish origin; journalist and broadcasting executive currently Chief Content Officer at Channel 4, overseeing all editorial decision making and commissioning across Channel 4's linear channels, streaming services and social media. Katz originally followed a career in print journalism, and was a deputy editor of The Guardian until 2013. He then became the editor of the Newsnight current affairs programme on BBC Two, a role which he left in late 2017 to join Channel 4. Mike Katz, chair of the Jewish Labour Movement; journalist for Jewish News, The Jewish Chronicle, Times of Israel, The Guardian, Forbes, Harvard Business Review, The Business Journals, HuffPost UK, New Statesman, LabourList, Camden New Journal, writing mainly on the theory of 'the new anti-Semitism' in Jeremy Corbyn's Labour Party and the demise of his leadership.
Several studies have also found these tests to be less sensitive than skin testing for the detection of clinically relevant allergies. False positive results may be obtained due to cross-reactivity of homologous proteins or by cross-reactive carbohydrate determinants (CCDs). In the NIH food guidelines issued in December 2010 it was stated that "The predictive values associated with clinical evidence of allergy for ImmunoCAP cannot be applied to other test methods." With over 4000 scientific articles using ImmunoCAP and showing its clinical value, ImmunoCAP is perceived as "Gold standard" for in vitro IgE testing
==== Nucleobases ==== Nucleobases, such as guanine and adenine, can be synthesized from simple carbon and nitrogen sources, such as hydrogen cyanide (HCN) and ammonia. On early Earth, HCN was likely supplied via photochemical production in a transient, highly reducing atmosphere after major impacts. Formamide, from the reaction of water and HCN, produces all four ribonucleotides when warmed with terrestrial minerals. HCN can contribute to chemical processes such as the synthesis of the amino acid glycine. DNA and RNA components including uracil, cytosine and thymine can be synthesized under outer space conditions, using starting chemicals such as pyrimidine from meteorites. Pyrimidine may have formed in red giant stars, interstellar dust, or gas clouds, or on Earth via precursors such as cyanoacetylene following asteroid impacts. All four RNA-bases may be synthesized from formamide in high-energy density events like extraterrestrial impacts. Several ribonucleotides for RNA formation have been synthesized in a laboratory environment which replicates prebiotic conditions via autocatalytic formose reaction. Other pathways for synthesizing bases from inorganic materials have been reported. Freezing temperatures assist the synthesis of purines, by concentrating key precursors such as HCN. However, while adenine and guanine require freezing conditions, cytosine and uracil may require boiling temperatures. Seven amino acids and eleven types of nucleobases formed in ice when ammonia and cyanide were left in a freezer for 25 years.
== Symptoms and signs == Prolidase deficiency generally becomes evident during infancy, but initial symptoms can first manifest anytime from birth to young adulthood. The condition results in a very diverse set symptoms, the severity of which can vary significantly between patients, depending on the degree to which prolidase activity is hampered by the individual underlying mutation(s) in each case. It is even possible, though rare, for affected individuals to be asymptomatic, in which case the disorder can only be identified through laboratory screening of the prospective patient and/or their extended family. One of the signature features of PD is the elimination of high quantities of peptides through urine. In addition, most of those affected exhibit persistent skin lesions (starting from a mild rash) or ulcers, primarily on the legs and feet, the formation of which normally begins during childhood. Clinically, these, among other dermatological issues, represent the most distinguishing and most frequent symptoms. These may never recede, potentially leading to severe infections that can, in the worst case, necessitate amputation. PD patients exhibit a weak immune system and markedly elevated vulnerability to infections in general, and particularly those of the respiratory system, leading some who suffer from PD to acquire recurrent lung disease. They may also have an enlarged spleen (splenomegaly), and on some occasions the spleen and liver may both be enlarged (hepatosplenomegaly). Photosensitivity and hyperkeratosis have been associated with PD.
6 RCN + 4 (NSCl)3 → 6 [RCN2S2]+Cl− + 3 Cl2 + 3 N2 Sulfur trioxide successively oxidizes the compound at the sulfur atoms to (NSOCl)3. The latter is also the pyrolysis product of a mixture of phosphorus pentachloride and sulfamic acid. In principle, it exists as stereoisomers, but only one (all chlorides axial) had been isolated by 1979.
Sources: en.wikipedia.org
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.
Reported human trials are few, brief and originate mainly from one country. They describe effects on anxiety-related measures, but sample sizes are small and reporting is limited. The results are widely regarded as preliminary rather than confirmed.
Reverse-phase liquid chromatography is used to assess purity and separation of related impurities. Mass spectrometry confirms that the observed molecular mass matches the expected peptide. A certificate of analysis from the supplier is the usual document of record.
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.